1-[(1-methyl-1 H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis

Journal of Medicinal Chemistry

Volumn 54, Issue 6, 2011, Pages 1724-1739

  Zhang, Lei ^a   Brodney, Michael A ^a   Candler, John ^a   Doran, Angela C ^a   Duplantier, Allen J ^a   Efremov, Ivan V ^a   Evrard, Edel ^a   Kraus, Kenneth ^a   Ganong, Alan H ^a   Haas, Jessica A ^a   Hanks, Ashley N ^a   Jenza, Keith ^a   Lazzaro, John T ^a   Maklad, Noha ^a   McCarthy, Sheryl A ^a   Qian, Weimin ^a   Rogers, Bruce N ^a   Rottas, Melinda D ^a   Schmidt, Christopher J ^a   Siuciak, Judith A ^a   Tingley III, F David ^a   Zhang, Andy Q ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(1 METHYL 1H IMIDAZO[4,5 B]PYRIDIN 2 YL)METHYL] 4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 3 OL; 1 [(1METHYL 1H IMIDAZOL 2 YL)METHYL] 4 PHENYLPIPERIDINE DERIVATIVE; 1 BENZYL 4 [4 (TRIFLUOROMETHYL)PHENYL] 1,2,3,6 TETRAHYDROPYRIDINE; 1 METHYL 2 [(4 PHENYLPIPERIDIN 1 YL)METHYL] 1 METHYL 1H BENZO[D]IMIDAZOLE; 1 METHYL 2 [[2 METHYL [4 (4 TRIFLUOROMETHYL 2 FLUORO)PHENYL]PIPERIDIN 1 YL]METHYL] 1H IMIDAZO[4,5 B]PYRIDINE; 1 METHYL 2 [[3 METHYL [4 (4 TRIFLUOROMETHYL 2 FLUORO)PHENYL]PIPERIDIN 1 YL]METHYL] 1H IMIDAZO[4,5 B]PYRIDINE; 1 METHYL 2 [[3 METHYL [4 (4 TRIFLUOROMETHYL 2 METHOXY)PHENYL]PIPERIDIN 1 YL]METHYL] 1H IMIDAZO[4,5 B]PYRIDINE; 1 METHYL 2 [[4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 1 YL]METHYL] 1H BENZO[D]IMIDAZOLE; 1 METHYL 2 [[4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 1 YL]METHYL] 1H IMIDAZO[4,5 B]PYRIDINE; 1 METHYL 2 [[4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 1 YL]METHYL] 1H IMIDAZO[4,5 C]PYRIDINE; 2 [[4 (2 CHLOROPHENYL)PIPERIDIN 1 YL]METHYL] 1 METHYL 1H BENZO[D]IMIDAZOLE; 2 [[4 (2 FLUOROPHENYL)PIPERIDIN 1 YL]METHYL] 1 METHYL 1H BENZO[D]IMIDAZOLE; 2 [[4 (2 METHOXYPHENYL)PIPERIDIN 1 YL]METHYL] 1 METHYL 1H BENZO[D]IMIDAZOLE; 2 [[4 (3 FLUOROPHENYL)PIPERIDIN 1 YL]METHYL] 1 METHYL 1H BENZO[D]IMIDAZOLE; 2 [[4 (4 CHLORO 2 FLUOROPHENYL)PIPERIDIN 1 YL]METHYL] 1 METHYL 1H BENZO[D]IMIDAZOLE; 2 [[4 (4 FLUOROPHENYL)PIPERIDIN 1 YL]METHYL] 1 METHYL 1H BENZO[D]IMIDAZOLE; 2 [[4 [2 FLUORO 4 (TRIFLUOROMETHOXY)PHENYL]PIPERIDIN 1 YL]METHYL] 1 METHYL 1H IMIDAZO[4,5 B]PYRIDINE; 2 [[4 [2 FLUORO 4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 1 YL]METHYL] 1 METHYL 1H IMIDAZO[4,5 B]PYRIDINE; 2 [[4 [2 METHOXY 4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 1 YL]METHYL] 1 METHYL 1H IMIDAZO[4,5 B]PYRIDINE; 3 [1 [(1 METHYL 1H BENZO[D]IMIDAZOL 2 YL)METHYL]PIPERIDIN 4 YL]BENZONITRILE; 3 METHYL 2 [[4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 1 YL]METHYL] 1H IMIDAZO[4,5 B]PYRIDINE; 3 METHYL 2 [[4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 1 YL]METHYL] 1H IMIDAZO[4,5 C]PYRIDINE; 3,3 DIMETHYL 4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN; 4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERIDIN 3 OL; HALOPERIDOL; METABOTROPIC GLUTAMATE RECEPTOR 2 POSITIVE ALLOSTERIC MODULATOR; METABOTROPIC RECEPTOR 2; N METHYL 3 [1 [(1 METHYL 1H BENZO[D]IMIDAZOL 2 YL)METHYL]PIPERIDIN 4 YL]BENZAMIDE; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HYPERACTIVITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PSYCHOSIS; RAT; SCRATCHING; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL AVAILABILITY; BRAIN; CELL LINE; DOGS; HUMANS; HYPERKINESIS; IMIDAZOLES; METHAMPHETAMINE; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; PIPERIDINES; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952796450     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101414h     Document Type: Article

References (33)

1. Poisik, O.; Raju, D. V.; Verreault, M.; Rodriguez, A.; Abeniyi, O. A.; Conn, P. J.; Smith, Y. Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus Neuropharmacology 2005, 49, 57-69 (Pubitemid 41115893)
2. Linden, A.-M.; Schoepp, D. D. Metabotropic glutamate receptor targets for neuropsychiatric disorders Drug Discovery Today: Ther. Strategies 2006, 3, 507-517 (Pubitemid 46076174)
3. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial Nature Med. 2007, 13, 1102-1107 (Pubitemid 47517511)
4. Fell, M. J.; Svensson, K. A.; Johnson, B. G.; Schoepp, D. D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1 R,4 S,5 S,6 S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) J. Pharmacol. Exp. Ther. 2008, 326, 209-217 (Pubitemid 351872145)
5. Recasens, M.; Guiramand, J.; Aimar, R.; Abdulkarium, A.; Barbanel, G. Metabotropic glutamate receptors as drug targets Curr. Drug Targets 2007, 8, 651-681 (Pubitemid 46785063)
6. B receptor desensitization Neuropharmacology 2008, 55, 1293-1299
7. For recent reviews, see Fraley, M. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia Expert Opin. Ther. Pat. 2009, 19, 1259-1275
8. Gasparini, F.; Spooren, W. Allosteric modulators for mGlu receptors Curr. Neuropharmacol. 2007, 5, 187-194 (Pubitemid 351863860)
9. Rudd, M. T.; McCauley, J. A. Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2) Curr. Top. Med. Chem. 2005, 5, 869-884 For more recent publications, see the following: Tresadern, G.; Cid, J. M.; Macdonald, G. J.; Vega, J. A.; De Lucas, A. I.; Garcia, A.; Matesanz, E.; Linares, M. L.; Oehlrich, D.; Lavreysen, H.; Biesmans, I.; Trabanco, A. A. Scaffold hopping from pyridone to imidazo[1,2-a]puridines. New positive allosteric modulators of metabotropic glutamate 2 receptor Bioorg. Med. Chem. Lett. 2010, 20, 175-179 (Pubitemid 41282355)
10. Brnardic, E. J.; Fraley, M. E.; Garbaccio, R. M.; Layton, M. E.; Sanders, J. M.; Culberson, C.; Jacobson, M.; Magliaro, B. C.; Hutson, P. H.; O'Brien, J. A.; Huszar, S. L.; Uslander, J. M.; Fillgrove, K. L.; Tang, C.; Kuo, Y.; Sur, S. M.; Hartman, G. D. 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts Bioorg. Med. Chem. Lett. 2010, 20, 3129-3133
11. Garbaccio, R. M.; Brnardict, E. J.; Fraley, M. E.; Hartman, G. D.; Hutson, P. H.; O'Brien, J. A.; Magliar, B. C.; Uslaner, J. M.; Huszar, S. L.; Fillgrove, K. L.; Small, J. H.; Tang, C.; Kuo, Y.; Jacobson, M. A. Discovery of oxazolobenzimidazoles as Postive Allosteric Modulators for the mGluR2 Receptor ACS Med. Chem. Lett. 2010, 1, 406-410
12. Cid, J. M.; Duvey, G.; Cluzeau, P.; Nhem, V.; Macary, K.; Raux, A.; Poirier, N.; Muller, J.; Bolea, C; Finn, T.; Urios, I.; Epping-Jordan, M.; Chamelot, E.; Derouet, F.; Girard, F.; MacDonald, G. J.; Vega, J. A.; De Lucas, A. I.; Matesanz, E.; Lavreysen, H.; Linares, M. L.; Oehlrich, D.; Oyarzabal, H.; Tresadern, G.; Trabanco, A. A.; Andres, J. I.; Le Poul, E.; Imogai, H.; Lutjens, R.; Rocher, J.-P. Discovery of 1, 5-disubstituted pyridines: A new class of positive allosteric modulators of the metabotropic glutamate 2 receptor ACS Chem. Neurosci. 2010, 1, 788-795
13. Zhang, L.; Rogers, B. N.; Duplantier, A. J.; McHardy, S. F.; Efremov, I.; Berke, H.; Qian, W.; Zhang, A. Q.; Maklad, N.; Candler, J.; Doran, A. C.; Lazzaro, J. T., Jr.; Ganong, A. H. 3-(Imidazolylmethyl)-3-aza-bicyclo[3.1.0] hexan-6-yl)methyl ethers: A novel series of mGluR2 positive allosteric modulators Bioorg. Med. Chem. Lett. 2008, 18, 5493-5496
14. Duplantier, A. J.; Efremov, I.; Candler, J.; Doran, A. C.; Ganong, A. H.; Haas, J. A.; Hanks, A. N.; Kraus, K. G.; Lazarro, J. T., Jr.; Lu, J.; Maklad, N.; McCarthy, S. A.; O'Sullivan, T. J.; Rogers, B. N.; Siuciak, J. A.; Spracklin, D. K.; Zhang, L. 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization Bioorg. Med. Chem. Lett. 2009, 19, 2524-2529
15. During the preparation of this manuscript, a structurally related series of mGluR2 PAMs was disclosed by D'Alessandro et al. For a reference, see D'Alessandro, P. L.; Corti, C.; Roth, A.; Ugolini, A.; Sava, A.; Montanari, D.; Bianchi, F.; Garland, S. L.; Powney, B.; Koppe, E. L.; Rocheville, M.; Osborne, G.; Perez, P.; De la Fuente, J.; De Los Frailes, M.; Smith, P. W.; Branch, C.; Nash, D.; Watson, S. P. The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2 Bioorg. Med. Chem. Lett. 2010, 20, 759-762
16. 20 glutamate challenge. Data are analyzed as a ratio of the peak fluorescence to the baseline after compound addition. Assay to assay variability in PAM potency required multiple experiments to determine potency, typically n > 3.
17. Hitchcock, S. A. Blood-brain barrier permeability considerations for CNS-targeted compound library design Curr. Opin. Chem. Biol. 2008, 12, 318-323
18. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-891
19. i = 426 nM). Compound 3 was also screened in mGluR1 (agonist, antagonist mode), mGluR5 (agonist, antagonist, PAM mode) functional assays with no activity detected up to 10 -M.
20. 2 receptors and measures the inhibition of quinpirole stimulation by the test compounds.
21. For a recent review, see Seeman, P. Targeting the dopamine D2 receptor in schizophrenia Expert Opin. Ther. Targets 2006, 10, 515-531
22. Jaen, J. C.; Wise, L. D. Synthesis of the 1,2,3,4-tetrahydrobenzofuro[2, 3-c]pyridine ring system J. Heterocycl. Chem. 1987, 24, 1317-1319
23. 50 values > 3000 nM); compounds (+)- 17c - e were also screened in mGluR1 (agonist, antagonist mode), mGluR5 (agonist, antagonist, PAM mode) functional assays with no activity detected up to 10 -M.
24. Yui, K.; Ikemoto, S.; Ishiguro, T.; Goto, K. Studies of Amphetamine or Methamphetamine Psychosis in Japan: Relation of Methamphetamine Psychosis to Schizophrenia Ann. N.Y. Acad. Sci. 2000, 914, 1-12
25. Hirota, S.; Kawashima, N.; Chaki, S.; Okuyama, S. Neuropharmacological Profile of an Atypical Antipsychotic, NRA0562 CNS Drug Rev. 2003, 9, 375-388 (Pubitemid 38031865)
26. Satow, A.; Maehara, S.; Ise, S.; Hikichi, H.; Fukushima, M.; Suzuki, G.; Kimura, T.; Tanaka, T.; Ito, S.; Kawamoto, H.; Ohta, H. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3- yl)-5-methyl-1 H -1,2,3-triazol-4-yl]- N -isopropyl- N -methyl-3,6- dihydropyridine-1(2 H)-carboxamide] J. Pharmacol. Exp. Ther. 2008, 326, 577-586
27. Marinozzi, M.; Natalini, B.; Constantino, G.; Tijskens, P.; Thomsen, C.; Pellicciari, R. Synthesis and Pharmacological Characterization of All Sixteen Stereoisomers of 2-(2-Carboxy-3-phenylcyclopropyl)glycine. Focus on (2 S,1- S,2- S,3- R)-2-(2-Carboxy-3-phenylcyclopropyl)glycine, a Novel and Selective Group II Metabotropic Glutamate Receptor Antagonist J. Med. Chem. 1996, 39, 2259-2269
28. Gross, G.; Wicke, K. M.; Mezler, M.; Schoemaker, H. Glutamate mGluR2/3 agonists inhibit mescaline-induced scratching in mice: A potential model of antipsychotic activity. 34th Annual Meeting of the Society for Neuroscience, 2004, abstract 1030.16.
29. Gonzalez-Maeso, J.; Weisstaub, N. V.; Zhou, M.; Chan, P.; Ivic, L.; Ang, R.; Lira, A; Bradley-Moore, M.; Ge, Y.; Zhou, Q.; Sealfon, S. C.; Gingrich, J. A. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior Neuron 2007, 53, 439-452 (Pubitemid 46161267)
30. Scruggs, J. L.; Schmidt, D.; Deutch, A. Y. The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats Neurosci. Lett. 2003, 346, 137-140 (Pubitemid 36829280)
31. Scruggs, J. L.; Patel, S.; Bubser, M.; Deutch, A. Y. DOI -induced activation of the cortex: Dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons J. Neurosci. 2000, 20, 8846-8852
32. Marek, G. J. A novel approach to the identification of psychiatric drugs: Serotonin-glutamate interactions in the prefrontal cortex CNS Drug Rev. 2000, 6, 206-218
33. Kalvass, J. C.; Maurer, T. S. Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery Biopharm. Drug Dispos. 2002, 23, 327-338 (Pubitemid 36124162)